| Literature DB >> 33203791 |
Yong Wang1, Hua Wei1, Jianhua Tong1, Muhuo Ji1, Jianjun Yang1.
Abstract
Although more patients survive sepsis and are increasingly discharged from the hospital, they often experience long-term cognitive and psychological impairment with significant socioeconomic impact. However, the pathophysiological mechanisms have not been fully elucidated. In the present study, we showed that LPS induced long-term neurobehavioral abnormities, as reflected by significantly decreased freezing time to context and sucrose preference. Using a high-throughput quantitative proteomic screen, we showed that phosphorylation of synaptic GTPase-activating protein 1 (pSynGAP1) was identified as the hub of synaptic plasticity and was significantly decreased following LPS exposure. This decreased pSynGAP was associated with significantly lower theta and gamma oscillations in the CA1 of the hippocampus. Notably, restoration of pSynGAP1 by roscovitine was able to reverse most of these abnormities. Taken together, our study suggested that pSynGAP1 disturbance-mediated hippocampal oscillation network impairment might play a critical role in long-term neurobehavioral abnormities of sepsis survivors.Entities:
Keywords: SynGAP; cognitive dysfunction; oscillation; proteomic
Mesh:
Substances:
Year: 2020 PMID: 33203791 PMCID: PMC7746391 DOI: 10.18632/aging.104080
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Figure 1(A) Timeline of the experimental procedures of the present study. (B) Effects of LPS on survival rate, n = 25 for control group, n = 40 for LPS group, and n=33 for LPS + roscovitine group. (C) Effects of CLP on survival rate, n = 22 for control group, n = 52 for CLP group. LPS, lipopolysaccharide; NS, normal saline, *P < 0.05.
Figure 2(A) Timeline of the proteins and phosphoproteins procedure. (B, C) Volcano plot indicating significantly altered proteins and phosphoproteins between control and LPS groups. (D, E) Heat map showing significantly altered proteins and phosphoproteins between control and LPS groups (n = 3). LPS, lipopolysaccharide; NS, normal saline; ITRAQ, isobaric tagging for relative and absolute quantitation; HPLC, High performance liquid chromatography.
Differential proteomics in hippocampus by iTRAQ analysis from control and LPS mice.
| Rars2 | Rars2 | 1 | 2.7681661 | 1.55797 | |
| Clic6 | Clic6 | 1 | 2.1812081 | 1.47219 | |
| Rttn | Rttn | 2 | 0.7637017 | 1.42522 | |
| Gtpbp10 | Gtpbp10 | 1 | 6.010929 | 1.42171 | |
| Itgb7 | Itgb7 | 1 | 1.1166253 | 1.4073 | |
| Hbb-bh0 | Hbb-bh0 | 1 | 6.8027211 | 1.39139 | |
| Sept10 | Sept10 | 1 | 3.7610619 | 1.37436 | |
| Mmp1a | Mmp1a | 1 | 3.6637931 | 1.35294 | |
| Eml1 | Eml1 | 1 | 1.3513514 | 1.34336 | |
| Krt8 | Krt8 | 3 | 8.9795918 | 1.29396 | |
| Ubqln4 | Ubqln4 | 1 | 7.7181208 | 1.27273 | |
| Serpini1 | Serpini1 | 1 | 5.6097561 | 1.27273 | |
| Ca5b | Ca5b | 1 | 5.362776 | 1.2531 | |
| Elmo1 | Elmo1 | 2 | 9.3535076 | 1.24682 | |
| Gng10 | Gng10 | 1 | 22.058824 | 1.22305 | |
| Smad1 | Smad1 | 1 | 3.0107527 | 0.81683 |
Figure 4Gene ontology (GO) classification for differentially expressed proteins. (A) For proteomes, populations of proteins that showed alteredexpression are indicated based on their GO for molecular function, biological process, and cellular components. (B) For phosphoproteomes, populations of proteins that showed alteredexpression are indicated based on their GO for molecular function, biological process, and cellular components.
Differential phosphoproteomics in hippocampus by iTRAQ analysis from control and LPS mice.
| P24788 | Cdk11b | Cyclin-dependent kinase 11B | 1.68937696 |
| Q9QYR6 | Map1a | Microtubule-associated protein 1A | 1.60799652 |
| P14869 | Rplp0 | 60S acidic ribosomal protein P0 | 1.60799652 |
| P14873 | Map1b | Microtubule-associated protein 1B | 1.58955546 |
| P47955 | Rplp1 | 60S acidic ribosomal protein P1 | 1.55754476 |
| Q9QYR6 | Map1a | Microtubule-associated protein 1A | 1.52737995 |
| P70704 | Atp8a1 | Phospholipid-transporting ATPase IA | 1.48797678 |
| O08788 | Dctn1 | Dynactin subunit 1 | 1.40730337 |
| Q91YM2 | Arhgap35 | Rho GTPase-activating protein 35 | 1.39043825 |
| P20357 | Map2 | Microtubule-associated protein 2 | 1.38893312 |
| Q9QWY8 | Asap1 | Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 | 1.36127509 |
| A2ARP1 | Ppip5k1 | Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 1 | 1.31979892 |
| Q9JIS5 | Sv2a | Synaptic vesicle glycoprotein 2A | 1.31570822 |
| Q80YE4 | Aatk | Serine/threonine-protein kinase LMTK1 | 1.30680507 |
| Q4QQM5 | Miga1 | Mitoguardin 1 | 1.30237913 |
| O54781 | Srpk2 | SRSF protein kinase 2 | 1.29231945 |
| Q9D7P6 | Iscu | Iron-sulfur cluster assembly enzyme ISCU, mitochondrial | 1.28783835 |
| Q8C8R3 | Ank2 | Ankyrin-2 | 1.27703985 |
| Q6PB44 | Ptpn23 | Tyrosine-protein phosphatase non-receptor type 23 | 1.25856229 |
| Q9JMH9 | Myo18a | Unconventional myosin-XVIIIa | 1.25818592 |
| Q8BP99 | UPF0500 protein C1orf216 homolog | 1.25309801 | |
| Q80TL4 | Phf24 | PHD finger protein 24 | 1.23094087 |
| Q8CC27 | Cacnb2 | Voltage-dependent L-type calcium channel subunit beta-2 | 1.21856509 |
| P56399 | Usp5 | Ubiquitin carboxyl-terminal hydrolase 5 | 0.83323152 |
| Q9Z2H5 | Epb41l1 | Band 4.1-like protein 1 | 0.83318057 |
| Q3UHJ0 | Aak1 | AP2-associated protein kinase 1 | 0.83262065 |
| Q01815 | Cacna1c | Voltage-dependent L-type calcium channel subunit alpha-1C | 0.83150183 |
| P14873 | Map1b | Microtubule-associated protein 1B | 0.83119658 |
| Q9WTX2 | Prkra | Interferon-inducible double-stranded RNA-dependent protein kinase activator A | 0.81518451 |
| Q8C8R3 | Ank2 | Ankyrin-2 | 0.81378476 |
| Q9EPJ9 | Arfgap1 | ADP-ribosylation factor GTPase-activating protein 1 | 0.8115942 |
| Q99JX3 | Gorasp2 | Golgi reassembly-stacking protein 2 | 0.80965309 |
| Q80TI0 | Gramd1b | GRAM domain-containing protein 1B | 0.80965309 |
| Q3V3V9 | Carmil2 | Capping protein, Arp2/3 and myosin-I linker protein 2 | 0.80856195 |
| Q9Z1B3 | Plcb1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 | 0.79802218 |
| Q9Z2H5 | Epb41l1 | Band 4.1-like protein 1 | 0.79533214 |
| Q9QWI6 | Srcin1 | SRC kinase signaling inhibitor 1 | 0.79265013 |
| F6SEU4 | Syngap1 | Ras/Rap GTPase-activating protein SynGAP | 0.79104478 |
| Q3TY60 | Fam131b | Protein FAM131B | 0.78890877 |
| Q7TME0 | Plppr4 | Phospholipid phosphatase-related protein type 4 | 0.78518298 |
| O88737 | Bsn | Protein bassoon | 0.78071217 |
| Q9JM52 | Mink1 | Misshapen-like kinase 1 | 0.77619893 |
| G3XA57 | Rab11fip2 | Rab11 family-interacting protein 2 | 0.77327816 |
| D3YVF0 | Akap5 | A-kinase anchor protein 5 | 0.77304965 |
| Q61097 | Ksr1 | Kinase suppressor of Ras 1 | 0.76626435 |
| P20357 | Map2 | Microtubule-associated protein 2 | 0.765 |
| Q3UHD9 | Agap2 | Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 2 | 0.76315016 |
| Q68EF6 | Begain | Brain-enriched guanylate kinase-associated protein | 0.75901495 |
| P33173 | Kif1a | Kinesin-like protein KIF1A | 0.75416545 |
| Q9R0K7 | Atp2b2 | Plasma membrane calcium-transporting ATPase 2 | 0.75416545 |
| Q9WV92 | Epb41l3 | Band 4.1-like protein 3 | 0.75 |
| Q924A2 | Cic | Protein capicua homolog | 0.74876129 |
| Q3UH99 | Shisa6 | Protein shisa-6 | 0.73690304 |
| O54829 | Rgs7 | Regulator of G-protein signaling 7 | 0.73589818 |
| P48453 | Ppp3cb | Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform | 0.73260179 |
| P97427 | Crmp1 | Dihydropyrimidinase-related protein 1 | 0.7323903 |
| Q9Z0P4 | Palm | Paralemmin-1 | 0.72860847 |
| Q8K2Y9 | Ccm2 | Cerebral cavernous malformations protein 2 homolog | 0.72612198 |
| Q9QYG0 | Ndrg2 | Protein NDRG2 | 0.72562554 |
| Q8CC35 | Synpo | Synaptopodin | 0.71604232 |
| Q9QYX7 | Pclo | Protein piccolo | 0.71253212 |
| Q3UHD9 | Agap2 | Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 2 | 0.70842825 |
| P04370 | Mbp | Myelin basic protein | 0.70426136 |
| Q9CYZ2 | Tpd52l2 | Tumor protein D54 | 0.69875425 |
| P35803 | Gpm6b | Neuronal membrane glycoprotein M6-b | 0.69491525 |
| O88703 | Hcn2 | Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 | 0.68586682 |
| Q6R891 | Ppp1r9b | Neurabin-2 | 0.67691448 |
| Q8BJ42 | Dlgap2 | Disks large-associated protein 2 | 0.67597765 |
| Q80TJ1 | Cadps | Calcium-dependent secretion activator 1 | 0.65425972 |
| O55131 | Sept7 | Septin-7 | 0.5560166 |
| Q5FWK3 | Arhgap1 | Rho GTPase-activating protein 1 | 0.54400412 |
Figure 3Expressions of cleaved caspase-3, cytochrome C, and MAP-2 in the hippocampus by western blotting analysis. (A) Representative Western blots bands of cleaved caspase-3, cytochrome C, and MAP-2 in the hippocampus; (B) Quantitative analysis of cleaved caspase-3, cytochrome C, and MAP-2. Data are presented as the mean ± SEM, n = 4, *P < 0.05.
Figure 5Protein–protein interaction (PPI) networks of differential proteins between control and LPS groups. The PPI analysis was based on fold change of protein–protein interaction, which showed SynGAP1 was identified as the hub of synaptic plasticity.
Figure 6Validation of Syngap1 and pSyngap1 in hippocampus by western blotting analysis. (A) Representative Western blots bands of Syngap1 and pSyngap1 in the hippocampus; (B) Quantitative analysis of Syngap1 and pSyngap1 levels between groups. Data are presented as the mean ± SEM, n = 4, *P < 0.05.
Figure 7Decreased hippocampal pCamKII, pSynGAP levels, and dendritic spine density following LPS challenge were rescued by roscovitine. (A, B) LPS induced significantly decreased hippocampal pCamKII and pSynGAP levels, which were prevented by roscovitine treatment. (C, D) LPS induced significantly increased hippocampal dendritic spine loss, which was reversed by roscovitine treatment. Data are presented as the mean ± SEM, n = 4, *P < 0.05 vs control group; #P < 0.05 vs LPS group. LPS, lipopolysaccharide.
Figure 8Decreased gamma oscillation in the CA1 of the hippocampus following LPS challenge was prevented by roscovitine. (A, B) Example recordings and example power spectra in the hippocampal. (C–F) Summary of LFP power, including θ, α, β, and γ oscillation. The theta and gamma oscillation powers were significantly lower in LPS group when compared with control group, which were prevented by roscovitine. Data are shown as mean ± SEM, n = 4, *P < 0.05 vs control group; #P < 0.05 vs LPS group. LPS, lipopolysaccharide; R, roscovitine.
Figure 9LPS-induced neurobehavioral abnormities were attenuated by roscovitine. (A) LPS had no effect on the total distance traveled, while roscovitine treatment significantly increased total distance traveled in LPS + roscovitine group compared with LPS group. (B) No difference in time spent in the center of the open arena was observed among groups. (C, D) There was no difference in time in the open arms and closed arms between groups. (E) LPS-induced significantly decreased the freezing time to context was reversed by roscovitine treatment. (F) There was no difference in freezing time to tone in the auditory-cued fear test among groups. (G) Decreased preference for sucrose in LPS-exposed mice was reversed by roscovitine treatment. (H) LPS significantly increased immobility compared with control group, which was not prevented by roscovitine treatment. Data are presented as the mean ± SEM, n = 10-12, *P < 0.05 vs control group; #P < 0.05 vs LPS group. LPS, lipopolysaccharide.
Figure 10CLP did not induce neurobehavioral abnormities. (A, B) CLP had no effect on the total distance traveled and time spent in the center of the open arena compared with sham group. (C, D) There was no difference in time in the open arms and closed arms between groups. (E, F) There was no difference in freezing time to context or tone in fear conditioning tests between groups. (G, H) CLP had no effect on preference for sucrose or immobility compared with sham group. Data are presented as the mean ± SEM, n = 10-12, *P < 0.05 vs sham group. CLP, cecal ligation and puncture.